ISSN 1662-4009 (online)

ey0019.4-4 | Important for clinical practice | ESPEYB19

4.4. Effects of growth hormone treatment on sleep-related parameters in adults with Prader-Willi syndrome

HH Shukur , L Hussain-Alkhateeb , Farholt S , O Norregaard , AP Jorgensen , C Hoybye

The Journal of Clinical Endocrinology & Metabolism, 2021, Vol. 106, No. 9, e3634–e3643PMID: 33950234Brief Summary: This trial explored the effects of rhGH treatment in patients with Prader-Willi syndrome (PWS) on respiratory and sleep parameters. The trial was randomized and placebo-controlled for 1 year, followed by a 2-year, open-phase GH treatment period. Polysomnography performed every 6 months revealed no adverse effects of rhGH tr...

ey0017.8-16 | New Paradigms | ESPEYB17

8.16. GDF15 is elevated in conditions of glucocorticoid deficiency and is modulated by glucocorticoid replacement

A Melvin , D Chantzichristos , CJ Kyle , SD Mackenzie , BR Walker , G Johannsson , RH Stimson , S O’Rahilly

To read the full abstract: J Clin Endocrinol Metab. 2020; 105(5): 1427–1434. PMID: 31853550.GDF15 is a stress-induced hormone that acts in the hindbrain to activate neural circuits involved in aversive responses and reducing food intake and body weight in animal models (1). In humans, GDF15 is widely expressed, with highest concentrations seen in placental trophoblasts, followed by kid...